Viking Therapeutics corrects statement on VK2735 oral maintenance trial dosing schedule
Viking Therapeutics issued a correction to its Oct. 6, 2026 release on the VK2735 oral maintenance dosing trial. The earlier release incorrectly stated the study would evaluate weekly oral doses. The trial will evaluate maintenance options including daily oral doses, selected subcutaneous schedules, or placebo. Disclai